2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has received approval from the U.S. FDA as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy. LEQEMBI IQLIK is scheduled to be launched in the U.S. in late August 2026 as an initial treatment.”